Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS-553 in Relapsed or Refractory B-cell Lymphoma
NCT05720052Phase 2Terminated
- Sponsor
- MingSight Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MS-553 in B cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), sponsored by MingSight Pharmaceuticals. Started Feb 2023; status: terminated.
02
Drugs
MS-553
03
Conditions
B cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05720052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720052.